Physician profile
Milan Patel
NPI 1952447476
$1,803.43
in general payments reported to CMS, 2019-2025
19 companies · $543 in 2025
The $543 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.87 · 2021: $49.30 · 2022: $428 · 2023: $323 · 2024: $367 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910 · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.22 |
| Education | $323.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $323.18 | 2023 | Abilify |
| Pfizer INC. | $285.01 | 2024-2025 | |
| Abbott Laboratories | $208.71 | 2022 | |
| Abiomed | $201.58 | 2025 | |
| Amgen INC. | $166.35 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $119.44 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $117.38 | 2022 | |
| Biotronik INC. | $101.77 | 2022 | |
| Medtronic Vascular, INC. | $54.36 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $35.09 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.33 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $28.35 | 2025 | Wainua |
| Scpharmaceuticals INC. | $25.54 | 2025 | |
| Abbvie INC. | $23.48 | 2025 | |
| Merck Sharp & Dohme LLC | $19.52 | 2024 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $15.12 | 2019 | |
| Boston Scientific Corporation | $14.21 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $13.35 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.